CSE Bulletin: Consolidation - NeonMind Biosciences Inc.

CSE Bulletin: Consolidation - NeonMind Biosciences Inc.

NeonMind Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every four (4) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 32,144,140 common shares.

The name and symbol will not change.

Please note that all open orders will be cancelled at the close of business on April 14, 2022. Dealers are reminded to re-enter their orders taking into account the share consolidation.

_________________________________

NeonMind Biosciences Inc. a annoncé une consolidation de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-consolidée pour quatre (4) actions ordinaires pré-consolidées.

En conséquence, les actions en circulation de la société seront réduites à environ 32 144 140 actions ordinaires.

Le nom et le symbole ne changeront pas.

Veuillez noter que tous les ordres ouverts seront annulés à la fermeture des bureaux le 14 avril 2022. Il est rappelé aux concessionnaires de saisir à nouveau leurs ordres en tenant compte du regroupement d'actions.

Trading on a Consolidated Basis/Négociation sur une base consolidée:

le 18 avril/April 2022

Record Date/Date d'enregistrement:

le 19 avril/April 2022

Symbol/Symbole:

NEON

NEW/NOUVEAU CUSIP:

64051V 30 3

NEW/NOUVEAU ISIN:

CA 64051V 30 3 9

Old/Vieux CUSIP & ISIN:

64051V105/CA64051V1058

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

NEON:CC
The Conversation (0)
NeonMind Biosciences

NeonMind Biosciences

Using Psychedelics as Treatment for Mental Health Disorders and Weight Management

Using Psychedelics as Treatment for Mental Health Disorders and Weight Management Keep Reading...
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / lobe sciences ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported... Keep Reading...
Solvonis Therapeutics

U.S. Patent allowance received for PTSD discovery programme

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces that it has received a Notice of Allowance (the "Allowance") from the United States Patent and Trademark Office ("USPTO")... Keep Reading...
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / lobe sciences ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Change of auditorsOn October 10,... Keep Reading...
Numinus Wellness Announces Change of Auditor

Numinus Wellness Announces Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as... Keep Reading...
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...

Interactive Chart

Latest Press Releases

Related News